Review
Copyright ©2010 Baishideng.
World J Hepatol. Mar 27, 2010; 2(3): 114-126
Published online Mar 27, 2010. doi: 10.4254/wjh.v2.i3.114
Figure 3
Figure 3 A collaborative approach to target the CSCs. The hepatic CSCs identifications and their functional significances, including multidrugs resistance behavior and aberrant signaling pathways should be clearly identified. Together with CSCs markers, clinical aspects such as drug delivery system, single or combination therapy, drug dose and toxicity will support the potential of therapy. Both biological and clinical considerations will be potent means to improve the safety and efficiency of CSCs-targeted therapy.